Throughout the body, immune cells of various types, both classical (such as T-cells) and less recognized (such as intestinal epithelial cells) are exposed to a variety of neurotransmitters secreted from local nerve fibers. Moreover, immune cells express specific neurotransmitter receptors. Based on the above we asked whether neurotransmitters, by direct interaction with their receptors, can either evoke or block immune functions in general, and cytokine secretion in particular.
Introduction
Despite the conceptual dogma of a 'language' barrier between effector molecules used for communication within the immune, nervous and endocrine systems, an increasing body of data supports the concept of dynamic interactions between these systems [1, 2] . The details of these functional intercommunications remains however to a great extent unknown. Of specific interest are recent studies describing the anatomical basis of the assumed neuro-immune interplay, showing that all the primary and secondary lymphoid organs (among them the thymus, spleen, lymph nodes, bone marrow and gut) are massively innervated by nerves which release a variety of neurotransmitters and neuropeptides [3, 4] . Within these lymphoid organs, various immune cells including T cells, B cells, mast cells reside in close association to neurotransmitter-containing nerve fibers, and are thus most probably exposed to these neuronal molecules [3, 4] . In addition, within non-lymphoid organs, such as the brain, patrolling lymphocytes (primarily T cells) most certainly encounter various neurotransmitters under physiological and pathological conditions.
Various cells of the immune system, among them T cells and B cells were reported to express specific receptors for various neurotransmitters on their surface [7] [8] [9] [10] [11] [12] [13] [14] [15] . On these grounds, an intriguing critical question is whether specific neurotransmitters can directly turn on/ off specific immune functions [16] [17] [18] [19] . Such interactions may bear important clinical implications for the understanding of various diseases in which the immune system is either up-or down-regulated, and for designing neurotransmitter (or their antagonists)-based treatments to augment beneficial immune function when absent (e.g. to attack specific tumors), or to suppress it when it becomes detrimental (e.g. autoimmune diseases, chronic inflammation, immune-cell malignancies, neuroendocrine tumors).
The neuropeptides chosen to address this question are those reported to be present where immune cells reside or pass through under normal and/or pathological conditions, and to which immune cells bear surfaceexpressed receptors. Among the candidates clearly meeting these criteria are the four peptidergic neurotransmitters: Substance P (Sub P), Neuropeptide Y (NPY), Somatostatin (SOM) and Calcitonin gene-related peptide (CGRP).
The immune function chosen to be studied is cytokine secretion, a central effector feature of immune cells. A myriad of immune reactivities and diseases are mediated by, and dependent on, specific cytokines secreted from various immune cells [20] [21] [22] . More specifically, in recent years it has become evident that specific immune responses and diseases are associated with either T-helper (Th)l-type orTh2-type cytokine secretion [20] . Among those are anti-bacterial and anti-parasite immune responses, mucosal immune responses and systemic unresponsiveness (mucosally induced tolerance), autoimmune reactions and diseases, allergic responses and others. Furthermore, specific proinflammatory cytokines may have either detrimental or beneficial effects on specific neoplasias: on the one hand, elevated levels of proinflammatory cytokines were found within chronically inflamed tissues that show increased incidence of neoplasia, and, on the other, proinflammatory cytokines may assist in anti-tumor immune surveillance.
Can neuropeptides directly induce or block the cytokine secretion of immune cells?
Neuropeptides and T-cell cytokine secretion

The kaleidoscope of the T-cell cytokines
In general, CD4+ T cells can actually be divided into at least two major mutually exclusive subsets, Thl and Th2, distinguished according to their cytokine secretion profile [20, 21] . Upon antigenic-stimulation, Thl cells secrete mainly IL-2, IFN-y, and TNF-a. IFN-y stimulates the microbicidal activities of phagocytes, thereby promoting the intracellular destruction of phagocytized microbes. Thus, the principal effector function of Thl cells is in phagocyte-mediated defense against infections. The Thl cells are usually associated with inflammation, and induce cell-mediated responses [20] . Essential and beneficial immunity cannot take place without Thl cytokines, but their over-or dis-regulated production leads to numerous detrimental clinical consequences. In contrast, the characteristic cytokines produced by Th2 cells are IL-4, IL-5, IL-10 and IL-13. The Th2 cells induce B-cell proliferation and differentiation, and thus induce immunoglobulin production. TheTh2 subset is therefore associated with humoral-type immune responses, among them IgE-mast cell-dependent reactions. Cytokines from Th2 cells (mainly IL-4, IL-10 and IL-13) can also antagonize the effects of Thl cell-mediated reactivities. Thus, the Th2 cells can function as physiologic regulators of immune responses by inhibiting potentially injurious Thl responses [20] [21] [22] . The Thl and Th2 cells originate from pluripotent precursor ThO cells. Interestingly, the differentiation of ThO cells to either Thl or Th2 cells is determined predominantly by the cytokine environment (primarily by the respective levels of IFN-y, IL-12 and IL-4) [20] . The T cells themselves may participate in the Thl/Th2 decision process, through autocrine activation loops [20, 21] .
Cytokine secretion by helper T cells is particularly important in autoimmunity, since chronic autoimmune diseases, such as multiple sclerosis, diabetes and rheumatoid arthritis are predominantly caused by Thl cells. The Th2 cells, by virtue of antagonizing the Thl functions, can prevent and/or cure some of these autoimmune diseases [20] [21] [22] .
The current dogma is that the primary stimuli which drive ThO, Thl and Th2 cells into cytokine secretion are antigens processed and presented by antigen-presenting cells (APCs), and immunocyte-derived factors, such as cytokines and chemokines.
Can T cells be driven to secrete cytokines by direct and exclusive command of neuropeptides? If so, does the profile of the neuropeptide-triggered cytokine secretion resemble quantitatively and qualitatively the classical antigen-stimulated cytokine secretion?
Neuropeptides, by direct interaction with Tcells, induce cytokine secretion and break the commitment to a distinct Th phenotype
To investigate whether neuropeptides can directly stimulate T cells to secrete cytokines, and if so, to compare neuropeptide-induced vs. antigen-induced cytokine secretion, four neuropeptides: SOM, CGRP, NPY and Sub P were applied to mouse antigen-specific T cells, and their cytokine secretion determined [17] . Several ThO, Thl and Th2 cell lines and clones which differ in their cytokine secretion profile, were used. Upon 'classical'antigenic stimulation, the Thl cells typically secreted IL-2 and IFN-y, the Th2 cells secreted primarily IL-4 and IL-10, while the ThO cells secreted all the four cytokines (Figure la, middle graphs). In resting (nonstimulated) conditions, the cytokine secretion of these cells was very low.
Interestingly, we found that the above neuropeptides, at a physiological concentration of lOnM, and in the absence of any additional stimulatory molecules induced a significant secretion of cytokines from ThO, Thl and Th2 antigen specific T cells [17] . Moreover, comparing neuropeptide-driven vs. classical antigen-driven cytokine secretion from the ThO, Thl, Th2 mouse T-cell populations, we observed a very unexpected phenomenon: some neuropeptides drove committed Thl and Th2 populations to a 'forbidden' cytokine secretion: secretion of Th2 cytokines from a Thl T-cell line, and vice versa (Figure lb, middle graphs). Such a phenomenon could not be induced by classical antigenic stimulation. These observations suggest that neurotransmitters by themselves are not only a sufficient stimulus to trigger T-cell cytokine secretion, but that they can also drive committed Thl and Th2 cells to secrete cytokines which are different from those normally secreted by these cells. This observation further suggests that the distinction between ThO/Thl/Th2 T-cell subtypes, based on their cytokine secretion profile, refers only to an antigendriven stimulation (Figure la, right) . Neuropeptide-induced cytokine secretion may require the creation of a new classification. We hypothesize that the neuropeptides can induce atypical cytokine secretion from already committed T cells by de-differentiating them, and reverting them into the ThO-non-commited-like cells (Figure lb, right) . Studies are currently in progress to challenge and validate this hypothesis.
Context and conclusions
Studying the effects of different neurotransmitters on various T-cell functions, it appears that the context is crucial. This is represented schematically in Figure lc . Thus, the effect of a given neurotransmitter on a resting cell (which is often stimulatory) can differ from its effect (often inhibitory) on pre-activated (e.g. by an antigen, mitogen, anti-CD3 antibodies, phorbol esters) cells. Furthermore, simultaneous stimulation of T cells by an antigen and a neurotransmitter often results in yet a different outcome (often synergistic), differing from the effect of the separated stimuli.
Taken together, the conclusions emerging from these studies on the pattern and function of neuropeptidesinduced T-cell cytokine secretion demonstrate and suggest the following: 1. Neuropeptides can directly affect the cytokine secretion of naive as well as cultured T cells. 2. Certain neuropeptides can trigger an atypical cytokine secretion from committed T-cell populations. 3. Some neuropeptides can induce cytokine secretion of resting T cells, while others can only affect the cytokine secretion of activated (i.e. antigen-stimulated) T cells. 4.
The effect of a given neuropeptide on a given T-cell population can be either stimulatory or inhibitory, depending on: a) The activation state of the cells, b) The T-cell Th phenotype (ThO/Thl/Th2), and c) The lymphoid organ from which the T cells derived (spleen, thymus, etc.), d) The cytokine in question: a given neuropeptide may exert different effects on different cytokines secreted from the same cell population. 5. A neuropeptide-induced effect can be either synergistic, antagonistic or simply neutral with the antigen-induced cytokine secretion.
The two latter conclusions suggest that within a T cell there is a cross talk between messages transmitted via the TCR and via the specific neurotransmitter receptors. The observations also suggest that T cells posses a varaiety of pathways controlling the secretion of different cytokines. Based on all the above, we propose that a specific neurotransmitter should not be defined a priori as a stimulatory or inhibitory molecule, at least as far as its effects on immune functions are concerned, since it is the context of its interaction with the target cell that dictates the final outcome.
Be it as it may, both the typical and atypical cytokine secretion triggered directly by neuropeptides may lead to a potentially altered in vivo function and destiny of T cells. This may have numerous important implications in physiological and pathological conditions, since, as mentioned above, many diseases or their therapy are associated with either a Thl or Th2 profile of cytokine secretion.
An intriguing example demonstrating how all the above can be related to oncology is the observation that the frequency of malignant melanoma is extremely low among patients with anti-melanocytes autoimmue vitiligo syndrome. These (and other related observations) raise the possibility that detrimental autoimmune T cells may have beneficial anti-tumor immune reactivities, culminating in tumor elimination [23] . One may further speculate that by virtue of their direct effects on T cells in general and on autoimmune T cells in particular, neurotransmitters under specific conditions may influence (positively or negatively) tumor infiltrating lymphocytes, and tilt the balance for better (rejection and cure) or for worse (tumor progression).
Neuropeptides and intestinal epithelial cytokine secretion
The kaleidoscope of gastointestinal hormones and neuropeptides
Neuropeptides and hormones are abundant within the gastrointestinal (GI) mucosa and play an important role in the normal physiology, as well as in disease states within the intestine. The neuropeptides originate from multiple sources, among them nerve endings and specific endocrine cells such as G cells and D cells [24, 25] ,
The mode by which various intestinal peptides function within the GI tract is variable and allows for a wide array of physiologic activities. For example, peptides like gastrin, motilin and secretin are secreted locally within the gut lumen, but affect distant target cells that they reach via the blood stream, and thus function as hormones [24] . Other peptides, such as cholecystokinin (CCK.) and somatostatin (SOM), are secreted both from specific cells within the intestinal mucosa, as well as from nerve endings, and function both as locally-acting neuropeptides and as hormones that affect a variety of tissues [24] . A large number of additional peptides, such as vasoactive intestinal peptide (VIP), substance P and other tachykinins, function mainly as neuropeptides. This class of mediators is involved in multiple GI activities, such as acid secretion, motility and absorption of electrolytes and nutrients [24] . Accordingly, uncontrolled production of neuropeptides due to tumors that arise within the intestine or the pancreas results in protean clinical manifestations. The most common of these include gastrinomas that cause the Zollinger-Ellison syndrome, insulinomas, which result in hypoglycemia and vipomas, which cause the Verner-Morrison syndrome and glucagonomas [26] .
Recently, it became increasingly evident that neuropeptides may interact with various cells of the immune system and affect their function [27] . However, despite the fact that the neuropeptides are abundant within the GI tract, little is known regarding their specific effects on the mucosal immune system.
The immune function of the intestinal mucosa
The intestinal mucosa serves as a barrier between the microbial-rich lumen and the sterile internal milieu. This barrier function is achieved both by forming a physical barrier, as well as by the elicitation of a controlled and beneficial immune response, which can restrict the invasion of bacteria [28] . A number of studies have shown that intestinal epithelial cells perform important functions in the protective immunologic cascades of the intestine. Thus, epithelial cells were shown to secrete a wide array of pro-inflammatory chemokines and cytokines [29] . The secretion of such mediators may play a role in the recruitment of polymorphonuclear and mononuclear cells, which in turn perpetuate local inflammation. Furthermore, following exposure of the epithelial cells to a pathogen or to inflammation-associated TNFa, the epithelial cytokine and chemokine secretion varies with time and in regard to the profile of the specific molecules secreted. This suggests that the epithelial cells have an ongoing and dynamic role in the elicitation and propagation of the mucosal immune response [29, 30] . However, the ability to secret proinflammatory cytokines may be a two-edged sword, and lack of adequate control may result in chronic inflammation, tissue damage and may even ultimately culminate in malignant transformation [31] . Thus, in order to maintain health, it is necessary to achieve opposing requirements; to mount an inflammatory response by secretion of pro-inflammatory cytokines on one hand, and to tightly control it on the other. Can the gut neuropeptides participate in such control? Indeed, this seems an especially attractive option in view of their anatomic proximity to the epithelial cells and the expression of neuropeptide receptors by the epithelial cells [32] .
The effect of somatostatin on the proinflammatory cytokine and chemokinesecretion of intestinal epithelial cells
In the present study, we investigated the direct effects of somatostatin on the secretion of the proinflammatory chemokine IL-8 and the cytokine IL-lb from intestinal epithelial cells [33] . Somatostatin, locally secreted within the GI system from specific cells, as well as from nerve endings, functions both as a hormone and a neuropeptide, and may thus have rapid and extensive effects. Somatostatin was reported to diversely affect the immune system depending on the cell type and the specific biological setting. For example, previous studies have reported conflicting results and showed that somatostatin may either down-regulate cytokine secretion from mononuclear cells [34] , or up-regulate such secretion [35] . In addition, the aforementioned effects of somatostatin, indicate that it may induce both typical and atypical T-cell cytokine secretion.
As a model system for intestinal epithelial cells, we utilized two colonic epithelial cell lines: HT-29 and Caco-2 that were derived from colon carcinomas. These cell lines were shown to secrete pro-inflammatory mediators in a manner similar to freshly isolated epithelial cells [29] . Initially, we tested the effect of somatostatin on the spontaneous secretion of IL-8 ( Figure 2a ) and IL-1 (3 (data not shown) from the intestinal epithelial cells. We found that SOM, in a dose-dependent manner, significantly inhibited above 90% of the secretion of both mediators, reaching a maximum at a concentration of 3 nM [33] .
Importantly, the inhibitory effect of somatostatin was abrogated when the cells were preincubated with the specific somatostatin antagonist cyclo-somatostatin. This antagonism suggests that the somatostatin effect was mediated via direct interaction with its surfaceexpressed receptor.
The effect of somatostatin occurred in both transformed intestinal epithelial cells (i.e. HT-29 and Caco cells) which differ in their response to differentiationinducing signals. Thus, the effect of SOM was not a peculiarity of a single cell line.
In various in vivo situations, the cytokine and chemokine secretion by epithelial cells is augmented, possibly as a result of bacterial invasion or TNF±.stimulation. Indeed, these stimuli are used in vitro to provoke such secretion. Figure 2b shows that somatostatin inhibited the secretion of IL-8 that was induced by invasion of salmonella into the cells. Importantly, an effect similar to somatostatin was obtained using octreotide, which is a synthetic octapeptide that binds to the somatostatin receptor subtypes 2 and 5. HT-29 cells express receptor subtypes 1 and 5. Taken together, we suggest that the effect of somatostatin was most likely mediated by receptor subtype 5. As can be seen (Figure 2b insert) , cyclo-somatostatin abolished the inhibitory effects of both somatostatin and octreotide, confirming that their effects were specific in this setting as well. SOM also inhibited IL-8 and IL-lb secretion provoked by TNFastimulation, indicating its ability to block the epithelial cytokine secretion following different physiological relevant stimuli. Additional experiments, in which the levels of IL-8 and IL-ip m RNA were determined, indicated that the effect of somatostatin was mediated, at least in part, via regulation of mRNA-levels. Taken together, these findings suggest that somatostatin may play an important role in mucosal immune-homeostasis in both physiological and acute and chronic pathophysiological conditions such as infectious gastroenteritis and the chronic inflammatory bowel diseases ulcerative colitis and Crohn disease.
Concluding remarks
Our data indicate that in addition to their classical role as transmitters and mediators in the nervous system, neuropeptides have the potential to directly interact with their receptors on both T cells and intestinal epithelial cells, resulting in the induction or inhibition of cytokine production and secretion.
The neuropeptides impose both qualitative and quantitative effects on the cytokine secretion of these cells, which are determined (in nature and magnitude) by the specific milieu of the cells, and by their state of activation. These direct and local effects may be translated into further indirect immune consequences. For example, neuropeptide-induced secretion of IFNy by T cells, may drive intestinal epithelial cells to secrete specific chemokines. In turn, these chemokines may affect the type and quantity of the T cells recruited into the mucosa [36] .
In conclusion, by their direct and indirect effects, neuropeptides may play an important role in various immune responses within different lymphoid and nonlymphoid tissues. This insight may have crucial clinical implications on the understanding and treatment of different diseases in which the immune system is involved, including cancer.
